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Background: The sphingosine 1-phosphate (S1P) receptor modulator FTY720P (GilenyaW) potently reduces relapse
rate and lesion activity in the neuroinflammatory disorder multiple sclerosis. Although most of its efficacy has been
shown to be related to immunosuppression through the induction of lymphopenia, it has been suggested that a
number of its beneficial effects are related to altered endothelial and blood–brain barrier (BBB) functionality.
However, to date it remains unknown whether brain endothelial S1P receptors are involved in the maintenance of
the function of the BBB thereby mediating immune quiescence of the brain. Here we demonstrate that the brain
endothelial receptor S1P5 largely contributes to the maintenance of brain endothelial barrier function.
Methods: We analyzed the expression of S1P5 in human post-mortem tissues using immunohistochemistry. The
function of S1P5 at the BBB was assessed in cultured human brain endothelial cells (ECs) using agonists and
lentivirus-mediated knockdown of S1P5. Subsequent analyses of different aspects of the brain EC barrier included
the formation of a tight barrier, the expression of BBB proteins and markers of inflammation and monocyte
transmigration.
Results: We show that activation of S1P5 on cultured human brain ECs by a selective agonist elicits enhanced
barrier integrity and reduced transendothelial migration of monocytes in vitro. These results were corroborated by
genetically silencing S1P5 in brain ECs. Interestingly, functional studies with these cells revealed that S1P5 strongly
contributes to brain EC barrier function and underlies the expression of specific BBB endothelial characteristics such
as tight junctions and permeability. In addition, S1P5 maintains the immunoquiescent state of brain ECs with low
expression levels of leukocyte adhesion molecules and inflammatory chemokines and cytokines through lowering
the activation of the transcription factor NFκB.
Conclusion: Our findings demonstrate that S1P5 in brain ECs contributes to optimal barrier formation and
maintenance of immune quiescence of the barrier endothelium.
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Table 1 Clinical data of non-neurological controls
Case Age
(years)
Type
of MS
Sex Post-mortem
delay (h:min)
Disease
Duration
(years)
Cause of
death
Control 89 NA F 6 NA Old age
Control 89 NA M 16 NA Dehydration
Control 84 NA F 5 NA Resp. failure
NA=not applicable; m=male; f = female.
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The vasculature of the brain is specialized to function as
a barrier to protect the central nervous system (CNS) by
restricting entry of unwanted molecules and immune
cells into the brain. This so-called blood–brain barrier
(BBB) is composed of highly specialized brain endothe-
lial cells (ECs) that line the capillary wall. These specia-
lized ECs form a tight barrier by membrane efflux
pumps that drive cellular exclusion of unwanted com-
pounds and the expression of complex tight junctions
[1-4], which actively limit cellular infiltration into the
brain. The ECs are enclosed together with pericytes
within the basement membrane onto which astrocytes
firmly project their endfeet, thereby maintaining the bar-
rier properties within the endothelium [5]. Strikingly,
several neuroinflammatory and neurodegenerative dis-
eases such as multiple sclerosis (MS), human immuno-
deficiency virus-associated dementia, capillary cerebral
amyloid angiopathy and stroke are associated with an
impaired function of the BBB [6-9]. Especially in MS, an
altered BBB function leads to enhanced entry of immune
cells and potentially toxic compounds into the CNS
[10-12]. To date, it remains largely unknown which
mechanisms underlie the altered BBB in such neurological
disorders. The identification of targets to restore impaired
barrier function may provide novel tools for treatment.
Sphingosine 1-phosphate (S1P) binding G-protein-
coupled receptors (GPCRs) are thought to be involved
in the regulation of the vasculature. In general, S1P sig-
nals through five GPCRs belonging to the endothelial
differentiation gene (EDG) family which entails: S1P1
(EDG-1), S1P2 (EDG-5), S1P3 (EDG-3), S1P4 (EDG-6),
and S1P5 (EDG-8). The S1P receptors are coupled to dif-
ferent G-proteins resulting in divergent downstream sig-
naling pathways. For example, S1P1 is proposed to
couple to Gαi and Gαo whereas S1P5 is through to inter-
act with Gαi, Gαo, Gα12, and Gα13 [13]. Consequently,
signaling of S1P through its receptors affects a broad
variety of signaling processes ranging from pathways
involved in cell survival, proliferation, motility to differ-
entiation. S1P receptors are essential in proper vascular
development because deficiency of for example S1P1
results in early embryonic death due to defects in vascu-
lar maturation [14]. Moreover, numerous S1P-driven EC
responses are reported and are found to be crucial for
proper development, maintenance and regulation of per-
ipheral vascular beds. S1P-mediated effects on the func-
tion of the endothelium are attributed to modulation of
S1P1 and S1P3. S1P receptors are currently under exten-
sive investigation because clinical trials demonstrate sig-
nificant reduction of disease severity in neurological
(autoimmune) disease models by targeting these recep-
tors [15-19]. In addition, two phase III clinical trials
(TRANSFORMS, FREEDOMS) concerning the S1Preceptor modulator FTY720P (GilenyaW) for treatment
of relapsing remitting MS deliver robust data demon-
strating greatly reduced relapse rates, significant reduc-
tion in lesion activity, and lower risk of disability
progression [20,21].
The recent availability of non-selective and selective
S1P receptor agonists has led to an increasing amount
of data about S1P receptor expression and their impact
on cellular function in the CNS. Apparent CNS effects
of S1P receptor modulators such as FTY720P and S1P
itself are translated into for example reduced immune
cell infiltration across the brain vasculature [19,22-24].
Recently, we demonstrated increased astrocytic S1P1 and
S1P3 expression in active MS lesions and an anti-
inflammatory effect of FTY720P (active form of
FTY720) on primary human astrocyte cultures [25].
Interestingly, although S1P1-4 receptors are widely
expressed throughout the body, S1P5 expression is more
or less restricted to the brain. It was therefore the aim of
this study to investigate the involvement of S1P5 in
underlying inflammatory processes in the CNS leading
to MS lesion development. We here show that S1P5 is
primarily expressed on brain ECs in human brain sug-
gesting a key role of S1P5 in BBB maintenance. Our
functional studies show that S1P5 is not only crucial for
the maintenance of the BBB but is also a key modulator
of endothelial inflammation processes. Ultimately, spe-
cific targeting of vascular S1P5 and subsequent repair of
the BBB in patients with inflammatory disorders may
have therapeutic benefits.
Methods
Autopsy material
Brain tissue from three non-neurological controls
(Table 1) was obtained at rapid autopsy and immediately
frozen in liquid nitrogen or fixed in formalin (in collab-
oration with The Netherlands Brain Bank, coordinator
Dr. Huitinga). The Netherlands Brain Bank received per-
mission to perform autopsies for the use of tissue and
for access to medical records for research purposes from
the Ethical Committee of the VU University Medical
Center, Amsterdam, The Netherlands. Tissue samples
from control cases without neurological disease were
taken from the subcortical white matter. All controls, or
their next of kin, had given informed consent for
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Immunohistochemistry
For immunohistochemical analysis, 5-μm cryosections
were processed and stained as described previously [26].
Briefly, sections were incubated overnight at 4 °C with pri-
mary antibodies against S1P5 (1:200) (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA and Imgenex, San Diego,
CA, USA). Subsequently, sections were incubated with
EnVision+Dual Link (DAKO, Glostrup, Denmark)
according to the manufacturer’s description. Diaminoben-
zidine tetrachloride (DAB; DAKO, Glostrup, Denmark)
was used as the chromogen. Antibodies were diluted in
PBS containing 0.1% bovine serum albumin (BSA; Boeh-
ringer Mannheim, Mannheim, Germany), which also
served as a negative control. For colocalization studies,
sections were incubated for 30 minutes with 5% goat
serum. Subsequently, sections were incubated with pri-
mary antibodies as described above and with mouse anti-
CD31 (1:200; DAKO, Glostrup, Denmark). Sections were
then incubated with goat anti-mouse Alexa 488 and goat
anti-rabbit Alexa 594 secondary antibodies (1:400 Molecu-
lar Probes, Eugene OR, USA). Omission of primary anti-
bodies served as a negative control. Incubation of tissue
sections with isotype controls or no secondary antibody
showed no immunoreactivity.
Endothelial cell culture
The human brain EC line hCMEC/D3 was kindly pro-
vided by Prof. P-O. Couraud (Institut Cochin, Université
Paris Descartes, Paris, France) [27] and grown in Endo-
thelial Cell Basal Medium-2 supplemented with hEGF,Table 2 Primers
Primer Sequence Forward
S1P1 5′-TGCGGGAAGGGAGTATGTTT-3′
S1P2 5′-TCTCTACGCCAAGCATTATGTGC
S1P3 5′-TGCAGCTTCATCGTCTTGGAG-3′
S1P5 5′-CCTTGGTGGCATGTTGGG-3′
GLUT 5′-GCCCCTGTGAAGATTGAGAG-3′
BCRP 5′-AGATGGGTTTCCAAGCGTTCAT-
PGP 5′-GTCCCAGGAGCCCATCCT-3′
VE-cadherin 5′-TGACGTGAACGACAACTGGC-3′
Claudin-5 5′-GCCCCTGTGAAGATTGAGAG-3′
TNF-α 5′-CCAAGCCCTGGTATGAGCC-3′
IL-1β 5′-GCTGATGGCCCTAAACAGATG-3
IL-8 5′-TGAGAGTGGACCACACTGCG-3′
MCP-1 5′-ATCTCAGTGCAGAGGCTCGC-3′
VCAM 5′-TGAAGGATGCGGGAGTATATGA
ICAM 5′-TAGCAGCCGCAGTCATAATGGGhydrocortisone, GA-1000, FBS, VEGF, hFGF-B, R3-IGF-
1, ascorbic acid and 2.5% fetal calf serum (FCS; EGM-2,
Lonza, Basel, Switzerland). Cells were cultured as
described before [28].
Lentiviral shRNA for S1P5 knockdown
Selective gene knockdown was obtained by using a
vector-based short hairpin (sh) RNA technique as
described before [29]. Plasmids encoding S1P5-specific
shRNAs were obtained from Sigma (TRCN0000004752,
St Louis, MO, USA). Recombinant lentiviruses were pro-
duced by co-transfecting subconfluent HEK 293 T cells
with the specific expression plasmids and packaging
plasmids (pMDLg/pRRE, pRSV-Rev and pMD2G) using
calcium phosphate as a transfection reagent. HEK 293 T
cells were cultured in DMEM supplemented with 10%
FCS, 1% penicillin/streptomycin, in a 37 °C incubator
with 5% CO2. Infectious lentiviruses were collected 48
hours after transfection and stored at −80 °C. Subse-
quently, lentiviruses expressing S1P5-specific shRNA
were used to transduce hCMEC/D3 cells. Control cells
were generated by transduction with lentivirus expres-
sing non-targeting shRNA (SHC002, Sigma, St Louis,
MO, USA). Forty-eight hours after infection of hCMEC/
D3 cells with the shRNA-expressing lentiviruses, stable
cell lines were selected by puromycin treatment (2 μg/
ml). The expression knockdown efficiency was deter-
mined by quantitative PCR (qPCR).
Quantitative PCR
All oligonucleotides were synthesized by Ocimum Bioso-
lutions (Ocimum Biosolutions, Ijsselstein, The Nether-
lands) (Table 2), RNA was isolated using the AurumTMSequence Reverse
5′-CGATGGCGAGGAGACTGAAC-3′
-3′ 5′-TGGCCAACAGGATGATGGA-3′
5′-GCCAATGAAAAAGTACATGCGG-3′
5′-GGGTTCAGAAGTGAGTTGGG-3′
5′-CCCGAAGCAGCCAATCC-3′
3′ 5′-CCAGTCCCAGTACGACTGTGACA-3′
5′-CCCGGCTGTTGTCTCCATA-3′
5′-GACGCATTGAACAACCGATG-3′
5′-CCCGAAGCAGCCAATCC-3′
5′-GCCGATTGATCTCAGCGC-3′
′ 5′- GCAGAGGTCCAGGTCCTGG-3′
5′-TCTCCACAACCCTCTGCACC-3′
5′-GCACAGATCTCCTTGGCCAC-3′
-3 ′5′-TTAAGGAGGATGCAAAATAGAGCA-3
-3′ ′5′-AGGCGTGGCTTGTGTGTTCG-3
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the manufacturer’s instructions. cDNA was synthesized
with the Reverse Transcription System kit (Promega,
Madison, WI, USA) following manufacturer’s guidelines
as described previously [30]. qPCR reactions were per-
formed in an ABI7900HT sequence detection system
with the SYBR Green method (Applied Biosystems,
Carlsbad, CA, USA). Obtained expression levels of tran-
scripts were normalized to GAPDH expression levels.
Western blot
Cell homogenates were prepared by replacing the cul-
ture medium with sodium dodecyl sulfate (SDS) sample
buffer containing 5% ß-mercaptoethanol and subsequent
heating at 95 °C for 5 minutes. Samples were separated
by SDS-PAGE and blotted onto nitrocellulose mem-
branes. Membranes were blocked with Odyssey block
buffer and incubated with an antibody against S1P5
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). Bind-
ing was visualized using the OdysseyW Infrared Imaging
System after application of IgG labeled with Infrared dye
(IRdye) 800 (Rockland Immunochemicals, Gilbertsville,
PA, USA). For quantification, S1P5 .protein levels were
corrected for tubulin using a specific anti-tubulin anti-
body (Cedarlane, Canada). The basal expression of p65
in S1P5 knockdown and control cells was assessed with
a rabbit anti-p65 antibody (Cell Signaling Technology,
Danvers, MA, USA) followed by secondary donkey anti-
rabbit 800 (IRDye). Protein expression was normalized
to beta-actin (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) detected with donkey anti-goat 680 (IRDye).
Immunocytochemistry
Transduced (mock and S1P5) hCMEC/D3 cells were pla-
ted in collagen coated μ-slide 8 well slides (Ibidi, Mar-
tinsried, Germany) and cultured as described before.
Upon confluence, cells were cultured in Endothelial Cell
Basal Medium-2 containing 2,5% human serum and
5 ng/ml basic fibroblast growth factor (bFGF) overnight
and fixed in 4% formaldehyde (Sigma, St Louis, MO,
USA) in PBS (Gibco) in the presence of 0.5% Triton
(Sigma, St Louis, MO, USA). Cells were washed and
blocked with PBS containing 0.1% BSA (Sigma, St Louis,
MO, USA) and 5% normal goat serum (NGS). Subse-
quently, cells were incubated with mouse anti-VE-
cadherin primary antibody (1:500: Becton & Dickinson,
San Jose, CA, USA) in PBS containing 0.1% BSA and 5%
NGS overnight. Cells were washed and incubated with
goat anti-mouse Alexa 488 secondary antibody (1:400:
Molecular Probes, Eugene OR, USA). After washing the
cells with PBS, rhodamine phalloidin (1:300) (Molecular
Probes, Eugene OR, USA) was used for F-actin staining
and Hoechst (1:1000 Molecular Probes, Eugene OR,
USA) for nuclear staining.Electrical cell-substrate impedance sensing
Transendothelial electric resistance in confluent mono-
layers of hCMEC/D3 cells was measured using an elec-
trical cell-substrate impedance sensing (ECIS) model
ZTheta (Applied BioPhysics, NY, USA) and 8W10E+
arrays. In short, 300 μl cell suspension (1,0 × 105 cells)
was added to in each well in Endothelial Cell Basal
Medium-2 supplemented with 2,5% human serum and 5
ηg/ml bFGF. Cells were seeded in medium containing
dimethyl sulfoxide (DMSO; 1 μM serving as vehicle con-
trol), FTY720P (1 μM), or a S1P5 selective agonist (1 μM
compound 18, a kind gift from Professor Stephen
Hanessian, Université de Montreal, Montreal, Canada)
[31]. Prior to seeding the collagen-coated ECIS arrays
were equilibrated with growth medium and Rb values
were calculated using ECIS software version 1.2.55.0 PC.
Permeability of the brain endothelial layer
Permeability of human brain EC monolayers was ana-
lyzed as described previously [28]. hCMEC/D3 and
hCMEC/D3 S1P5 knockdown cells were seeded at con-
fluence onto collagen-coated Costar Transwell filter
(pore-size 0.4 μm; Corning Incorporated, Corning, NY,
USA) in growth medium containing 2.5% FCS and
grown for 4 days. Paracellular permeability to FITC-
dextran (150 kDa, 500 μg/ml in culture medium; Sigma,
St Louis, MO, USA-Aldrich) in the apical to basolateral
direction was assayed at various time points. Samples
were collected from the acceptor chambers for measure-
ment of fluorescence intensity using a FLUOstar Galaxy
microplate reader (BMG Labtechnologies, Offenburg,
Germany), excitation 485 nm and emission 520 nm.
Monocyte migration
Human blood monocytes were isolated from buffy coats
of healthy donors (Sanquin, Blood Bank, Amsterdam,
NL) by Ficoll gradient and CD14-positive beads [32].
Control and S1P5 knockdown hCMEC/D3 cells were
seeded at confluence onto collagen-coated Costar Trans-
well filters (pore-size 5 μm; Corning Incorporated, Corn-
ing, NY, USA) in growth medium containing 2.5% FCS
and were grown for 4 days. ECs were exposed to DMSO
(1 μM) as a vehicle control, FTY720P (1 μM) or S1P5
agonist (1 μM) agonist for 16 hours and washed prior to
addition of monocytes [31]. Hereafter, 100 μl 1.6 × 106/
ml primary human monocytes suspended in Endothelial
cell Growth medium-2 containing 2,5% FCS were added
to the upper compartment for 8 hours at 37°C, 5% CO2
in air. Next, the suspension in the lower compartment
containing transmigrated monocytes was harvested and
quantified using anti-CD14 beads (Flow-count fluoro-
spheres, BeckmanCoulter, Inc., Brea, CA, USA) and sub-
sequent FACScan flow cytometer (Becton & Dickinson,
San Jose, CA, USA) analyses.
van Doorn et al. Journal of Neuroinflammation 2012, 9:133 Page 5 of 15
http://www.jneuroinflammation.com/content/9/1/133Monocyte adhesion assay
Monocyte adhesion to confluent monolayers of control
and S1P5 knockdown hCMEC/D3 cells was analyzed by
using primary human monocytes isolated as described
before. Human monocytes were fluorescently labeled
with 0.5 μM calcein-Am (Molecular Probes, Eugene OR,
USA) and suspended in RPMI+ 0.5% BSA+25 mM
Hepes to a final concentration of 1 × 106 cells [33]. A
standard curve of human monocytes was made with 0,
12.5, 25, 50, and 100% of this cell suspension. ECs were
washed and monocytes were added and incubated for 5,
15, 30, and 60 minutes in a 37 °C incubator with 5%
CO2. Non-adherent cells were removed and adherent
cells were lysed with 0.1 M NaOH. Fluorescence inten-
sity was measured (FLUOstar Galaxy, BMG Labtechnol-
ogies, Offenburg, Germany; excitation 480 nm, emission
520 nm) and the number of adhered monocytes was cal-
culated using the standard [33].
Flow cytometric analysis
Control and S1P5 knockdown hCMEC/D3 cells were
detached from 24-well culture plates, washed and incu-
bated with monoclonal mouse anti-intercellular adhe-
sion molecule-1(ICAM-1) (Rek-1, 5 μg/ml, a kind gift
from the Department of Tumour Immunology, Univer-
sity Medical Center St. Radboud, Nijmegen, The Nether-
lands) or mouse anti-vascular cell adhesion molecule-1
(VCAM-1; AbD Serotec, UK) for 30 minutes at 4 °C [34].
Binding was detected using goat anti-mouse Alexa 488
(Molecular Probes, Eugene, OR). Omission of primary
antibodies served as negative control. To investigate the
role of Nuclear factor kappa-light-chain-enhancer of
activated B cells (NFκB) in the enhanced inflammatory
status of S1P5 knockdown cells, the cells were treated for
16 hours with 4 μM NFκB inhibitor Bay 11–7085 (Sigma,
MO, USA) or vehicle control. Fluorescence intensity
was measured using a FACS Calibur flow cytometer
(Becton & Dickinson, San Jose, CA, USA). The mean
fluorescence intensity was used as a measure for the
expression of ICAM-1 and VCAM-1.
Statistical analysis
Data are presented as ± SEM and were analyzed statis-
tically by means of single-column t-test. Statistical sig-
nificance was defined as *P <0.05, **P <0.002, and
***P <0.001.
Results
S1P5 is highly expressed by brain capillaries in the human
brain
The expression of the S1P5 was analyzed in the white
matter of non-neurological control patients. Immunohis-
tochemical staining with the two different anti-S1P5
antibodies, clone H-88 (Santa Cruz) (Figure 1a) andIMG-71372 (Imgenex) (Figure 1b), essentially yield iden-
tical results. Both antibodies revealed that human brain
capillaries in the white and the gray matter (not shown)
constitutively express S1P5. Colocalization studies using
the endothelial marker CD31 (PECAM-1; Figure 1c) to-
gether with antibodies against S1P5 (Figure 1d) identified
ECs as the most predominant S1P5 expressing cell type
within the human brain (Figure 1e). Gene expression
analysis of the different S1P receptors in hCMEC/D3
cells indicated that brain ECs express all S1P receptors
except S1P4 at different levels (S1P1> S1P5> S1P3>
S1P2 with S1P1 being the highest; Figure 1f ).FTY720P and a selective S1P5 agonist enhance
transendothelial electrical resistance
To investigate the role of S1P5 in brain EC barrier func-
tion, we measured paracellular resistance formation by
hCMEC/D3 cells while exposed to either FTY720P or
the selective S1P5 agonist [31] by means of ECIS. Our
results show that S1P receptor activation by the non-
selective S1P receptor agonist FTY720P significantly
increases barrier formation in comparison with control
cells (Figure 2a). At the same time, stimulation of the
brain ECs with the selective S1P5 agonist also signifi-
cantly enhanced barrier formation in comparison to con-
trols (Figure 2b), indicating that S1P5 agonism
modulates barrier formation. Moreover, treatment of
brain endothelial monolayers with both the non-selective
S1P receptor modulator FTY720P and the selective S1P5
agonist significantly reduced permeability of hCMEC/D3
cells for FITC-dextran (70kD) by 63.2%± 4.6 and
61.7 ± 5.0, respectively (Figure 2c).S1P agonism reduces transendothelial migration of
monocytes
We next studied the effect of FTY720P and the selective
S1P5 agonist on a hallmark of neuroinflammation,
namely monocyte migration across the brain EC barrier.
hCMEC/D3 cells were exposed to FTY720P or the se-
lective S1P5 agonist for 24 hours prior to the addition of
primary human monocytes. In concordance with the
results described above, treatment with both FTY720P
(Figure 3a) and the selective S1P5 agonist (Figure 3b)
resulted in reduced transmigration of monocytes as
compared to vehicle-treated hCMED/D3 cells. It is of
interest that the reduced transendothelial migration of
monocytes across treated ECs coincided with a
decreased mRNA expression of the leukocyte adhesion
molecule VCAM-1 (Figure 3c) and increased expression
of the cell–cell junction protein VE-cadherin (Figure 3d),
suggesting that S1P5 agonism reduced the inflammatory
status of the brain endothelium.
Figure 1 S1P5 is expressed in the human cerebrovasculature. Capillaries in white matter from non-neurological human controls show strong
S1P5 expression. Human S1P5 expression was determined with either the Santa Cruz (a) or the Imgenex (b) antibody both showing similar
staining patterns. Colocalization studies with the EC marker CD31 (c) confirmed that ECs express significant levels of S1P5 (d) in human brain
capillaries (e). S1P receptor RNA expression levels of hCMEC/D3 cells were determined by qPCR. S1P1 expression was most abundant while there
was no detectable level of S1P4 expression. Receptor expression was detected in the following order: S1P1> S1P5> S1P3> S1P2 where S1P1
expression level was set at 100% (f). RNA encoding for S1P4 was undetectable (n.d.). Data represent ± SEM of three independent experiments.
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To further elucidate the mechanism of the S1P5 at the
brain endothelium, we generated a brain EC line
(hCMED/D3 subclone E2) with reduced expression of
S1P5. Transduction of brain ECs with lentiviruses
expressing a S1P5-specific shRNAs reduced the expres-
sion of S1P5 as determined by qPCR to undetectable
levels (Figure 4a). Protein levels of S1P5 were reduced by
43% (Figure 4b). Of note, S1P5 knockdown cells also dis-
played reduced expression of other S1P receptors in-
cluding S1P1, S1P2 and S1P3 (Figure 4c). These findingssuggest that S1P5 regulates the expression of other S1P
receptors.
Next, ECIS analysis was performed to determine the
function of S1P5 in brain EC barrier formation. Interest-
ingly, S1P5 knockdown cells revealed reduced barrier in-
tegrity compared to control cells (Figure 5a). To further
delineate function of S1P5 on brain endothelial function,
we studied various other properties that are associated
with BBB functioning. First, S1P5 knockdown cells were
more permeable to FITC-dextrans compared to control
cells (Figure 5b), illustrating enhanced leakiness of the
Figure 2 S1P5 activation enhances barrier endothelial integrity.
S1P receptor modulators were used to determine their effect of the
transendothelial electrical resistance (TEER) as assayed through ECIS.
(a) The non-selective S1P receptor modulator FTY720P (10−6 M in
DMSO) enhanced the TEER of hCMEC/D3 cells to 1.32 ohm.
cm2 ± 0.02, n = 3 compared to vehicle control at final time point
(1.10 ohm.cm2 ± 0.03, n = 3). Statistical significance (t-test) is
indicated with asterisks: *P< 0.05 and **P< 0.005. (b) The selective
S1P5 agonist (10
−6 M in DMSO) enhanced TEER of hCMEC/D3 cells
to 1.91 ohm.cm2 ± 0.03, n = 4 at final time point compared to vehicle
control (1.72 ohm.cm2 ± 0.05, n = 4) (B). The Rb values represent the
mean± SEM of four independent experiments. Statistical significance
(t-test) is indicated with asterisks: *P< 0.05. (c) Both the non-
selective S1P receptor modulator FTY720P (10−6 M in DMSO) and
the selective S1P5 agonist (10
−6 M in DMSO) reduced permeability
of hCMEC/D3 cells for FITC-dextran (FD 70) by 63.2%± 4.6 (n = 4)
and 61.7%± 5.0 (n = 4), respectively. Fluorescence intensity values
represent mean± SEM of four individual experiments with hCMEC/
D3 value at 5hours set at 100% (100.0%± 11.8, n = 4). Statistical
significance (t-test) is indicated with asterisks: *P< 0.05.
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these data, S1P5 knockdown ECs displayed reduced ex-
pression levels of tight junction and adherent junction-
associated proteins such as claudin-5 and VE-cadherin
(Figure 5c). Our analyses further show that key BBB-
associated transporter proteins like the nutrient trans-
porter for glucose (GLUT-1), and the ATP-binding
cassette (ABC) transporters P-glycoprotein (Pgp) and
breast cancer resistant protein-1 (BCRP-1) were signifi-
cantly decreased (Figure 5d) upon S1P5 knockdown. Con-
sistent with the observed reduced VE-cadherin expressionlevel in S1P5 knockdown cells, we found impaired VE-
cadherin protein localization to the junctions in the S1P5
knockdown cells (Figure 5e). Together, these data show
that S1P5 has a crucial role in the maintenance of the bar-
rier phenotype in brain ECs.S1P5 contributes to the immune quiescence state of the
brain EC barrier
Under normal conditions, the brain endothelium pro-
motes immunoquiescence of the brain by a low expres-
sion of cell adhesion molecules and undetectable
detection of the production of proinflammatory cyto-
kines and chemokines, thereby limiting attraction and
subsequent transendothelial migration of leukocytes.
To investigate the role of S1P5 in the inflammatory
status of the brain endothelium, we studied gene expres-
sion levels of cytokines and chemokines known to be
involved in the neuroinflammatory attack such as the
chemokines monocyte chemoattractant protein-1 (MCP-
1: CCL2) and interleukin-8 (IL-8) and the proinflamma-
tory cytokines interleukin-1β (IL-1β), and tumor necrosis
factor-α (TNF-α). Upon S1P5 knockdown, mRNA levels
of MCP-1 and IL-8 as well as the levels of TNF- α and
IL-1 β increased dramatically (Figure 6a,b).
Interestingly, our results showed that activation of S1P
receptors, and in particular S1P5, reduced the expression
of adhesion molecules and enhanced the capacity of
brain ECs to prevent monocyte passage (Figure 3). We
next determined the function of S1P5 in these distinct
aspects of the BBB. As expected, knockdown of the S1P5
in brain endothelium enhanced the adhesion of mono-
cytes to, and migration of, monocytes through the endo-
thelium when compared to mock and control hCMEC/
D3 cells (Figure 7a,b).
Figure 3 Endothelial S1P5 activation decreases monocyte transmigration. FTY720P (10
−6 M in DMSO; a) and a S1P5 agonist (10
−6 M in
DMSO; b) were added to confluent monolayers of hCMEC/D3 cells for 24 hours. Monocyte migration was assayed by time lapse microscopy,
FTY720P treatment of the brain ECs reduced monocyte migration to 55.3%± 7.42 (n = 3) compared to control (106.0%± 6.14 n = 3; a) and
treatment with the selective S1P5 agonist reduced monocyte migration to 75.9%± 0.68 n = 3; b). Both FTY720P and S1P5 agonist treated cells
show reduced VCAM-1 expression (control: 100.0%± 17.0; S1P5 agonist 64.8%± 8.9, n = 3; c) and increased VE-cadherin expression (control:
100.0%± 8.5; S1P5 agonist: 126.3%± 2. 6, n = 3; d). Values represent the mean± SEM of three individual experiments each performed in triplicate
with controls set at 100%. Statistical significance (t-test) is indicated with asterisks: *P< 0.05 **P< 0.002 and ***P< 0.001.
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monocyte-endothelial interaction we next determined
the expression levels of adhesion molecules ICAM-1 and
VCAM-1 which are both known to be involved in the
adhesion and migration of monocytes [35]. Our results
show that both gene and protein expression levels of
VCAM-1 and ICAM-1 were significantly increased in
S1P5 knockdown cells compared to control cells
(Figure 7c,d). Together, these findings indicate that
steady-state presence of cell surface S1P5 strongly con-
tributes to the immune quiescence state of the BBB.
The inflammatory phenotype is partly mediated by NF-κB
activation
As both ICAM-1 and VCAM-1 expression are under the
control of the NF-κB signaling pathway, we studiedwhether brain endothelial S1P5 exert their anti-
inflammatory control through NF-κB. First we determined
the regulation of the total p65 subunit of NF-κB protein
content by western blot. As shown in Figure 8a, the S1P5
knockdown cells have an increased basal expression of the
p65 subunit of NF-κB when compared to control cells.
This increased NF-κB content, which might underlie the
increased expression of adhesion molecules, strongly sug-
gests that S1P5 modulation is involved in immune quies-
cence of brain ECs mediated by inhibition of NF-κB. The
selective NF-κB inhibitor Bay 11–7085 significantly
reduced the gene expression levels of both ICAM-1 and
VCAM-1 (Figure 8b,c). Interestingly, addition of Bay-
11–7085 to S1P5 knockdown resulted in relative decreased
gene expression levels of ICAM-1 and VCAM-1 com-
pared to the mock control cells. To reveal the effect of
Figure 4 S1P5 knockdown and downstream effects on endothelial S1P receptor expression. (a) A lentiviral shRNA technique was used to
knockdown the S1P5. Treatment of the brain ECs with specific shRNA clone E2 resulted in a non-detectable level of S1P5 RNA as measured by
qPCR. S1P5 RNA expression levels in control cells were set at 100%. (b) Western blot analysis shows a 43.1%± 2.12% reduction in S1P5 protein
levels when compared to control cells. (c) S1P receptor characterization in S1P5 knockdown cells show reduction in RNA expression levels of all
S1P receptors where S1P1 is reduced by 61% (non-targeting control:100.0%± 8.5, S1P5 knockdown: 38.9%± 1.8), S1P2 by 39% (non-targeting
control: 100.0%± 0.6, S1P5 knockdown: 60.8%± 3.3), and S1P3 by 87% (non-targeting control: 100.0%± 5.3; S1P5 knockdown 13.3%± 0.8). Again,
S1P4 remains undetectable (n.d.) Values represent the mean± SEM of n = 3. Statistical significance (t-test) is indicated with asterisks: **P< 0.002
and ***P< 0.001.
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expression of ICAM-1 and VCAM-1 was calculated. It
was shown that the ratio of reduction in ICAM-1 gene ex-
pression by inhibition of NF-κB in S1P5 knockdown cells
was increased over 2-fold compared to 1.6-fold in mock
cells. Identically, the ratio of reduction in VCAM-1 gene
expression by inhibition of NF-κB in S1P5 knockdown
cells is increased to over 10-fold compared to 7.3-fold in
mock cells.
Discussion
Our present study demonstrates the constitutive expres-
sion of the S1P receptor S1P5 by brain ECs, constitutingthe BBB in human brain and its involvement in both in-
tegrity and regulation of the inflammatory status of the
brain endothelium. We have delineated a role for S1P5
in the induction of specific BBB properties such as low
paracellular permeability and the expression of key brain
endothelial proteins such as tight junction and specific
ATP binding cassette and glucose transporter molecules.
We have assessed the potential therapeutic improve-
ments upon pharmacological modulation of S1P5 recep-
tor activity in gaining barrier function. Moreover, the
lack of S1P5 provoked a proinflammatory status of brain
endothelium as shown by enhanced transendothelial mi-
gration of monocytes and increased production of
Figure 5 S1P5 regulates several key features of barrier endothelium. (a) ECIS was used to measure the impedance of the brain endothelial
monolayer. S1P5 knockdown cells (1.0 ohm.cm
2 ± 0.1) have over 40% reduction in TEER compared to mock cells (1.8 ohm.cm2 ± 0.02). Rb values
represent the mean± SEM of four individual experiments. (b) Paracellular permeability was studied by passive leakage of FITC-dextran molecules
(70kD). S1P5 knockdown cells (224.1%± 4.6 at 5 h) were more permeable FITC-dextrans in time compared to control and mock transduced ECs
(133.4%±6.1 at 5 h). Fluorescence intensity values represent mean± SEM of four individual experiments with hCMEC/D3. (c) qPCR analysis of
tight junction-associated proteins in S1P5 knockdown cells compared to control cells revealed a 57% decrease in claudin-5 expression
(non-targeting control: 100.0%± 19.4; S1P5 knockdown 42. 8%± 1.8, n = 3) and a 30% decrease in VE-cadherin expression (non-targeting control:
100.0%± 2.9; S1P5 knockdown 69.8%± 3.2, n = 3). (d) qPCR analysis of transporters expressed at the BBB revealed a 23% decrease in GLUT-1
expression (non-targeting control: 100.0%± 5.1; S1P5 knockdown 77.1%± 4.7, n = 3), 55% decrease in Pgp expression (non-targeting control:
100.0%± 8.1; S1P5 knockdown 44.5%± 1.60, n = 3), and 93% decrease in BCRP1 expression (non-targeting control: 100.0%± 3.5; S1P5 knockdown
7.0%± 1.4, n = 3). (e) VE-cadherin localization was also studied by immunocytochemistry. Reduced junctional VE-cadherin localization was observed
in S1P5 knockdown cells compared to control cells (VE-cadherin, green and F-actin, red). Statistical significance (t-test) is indicated with asterisks:
*P< 0.05, **P< 0.002 and ***P< 0.001.
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leukocytes, a process which was mediated by NF-κB
activation.
Within our findings, we showed the non-selective S1P
receptor agonist FTY720P and a selective S1P5 agonistboth improve brain endothelial function through the in-
crease of the paracellular resistance in the immortalized
human brain EC line, hCMEC/D3. This cell line reflects
the key features of primary brain ECs such as high
TEER, expression of tight junctions and transporter
Figure 6 S1P5 knockdown abolishes the immune quiescent
state of the brain endothelial cell barrier. (a) RNA expression of
proinflammatory cytokines and chemokines were assayed by qPCR.
RNA expression of the chemokines MCP-1 and IL-8 are increased by
78% (control: 100.0%± 5.6; S1P5 knockdown 178.1%± 9. 9, n = 3) and
171% (control: 100.0%± 6.7; S1P5 knockdown 271.4%±16.3, n = 3)
respectively in S1P5-deficient cells compared to mock cells. (b)
Levels of the endothelial cytokines were increased upon S1P5
deficiency, IL-1β by 442% (control: 100.0%± 7.1; S1P5 knockdown
541.5%± 58. 5, n = 3) and TNF-α by 138% (control: 100.0%± 22.9;
S1P5 knockdown 238.4%± 24.7, n = 3). Statistical significance (t-test)
is indicated with asterisks: *P< 0.05, **P< 0.002 and ***P< 0.001.
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on the endothelial barrier enhancing effect of FTY720P
on pulmonary ECs, human microvascular ECs, andhuman umbilical vein ECs [22,36-38]. However, we are
the first to show that selective activation of S1P5 induces
a significant increase in paracellular resistance of brain
ECs. Moreover, in concordance with ECs exposed to
FTY720P, brain endothelium exposed to a selective S1P5
agonistic compound prevented the transendothelial pas-
sage of monocytes in a similar fashion [31]. Enhanced
endothelial barrier integrity is probably the result of the
enhanced expression of tight junction and adherent
junction proteins and their localization at the cell–cell
contacts, as was shown in this study. To date, there is
emerging evidence that S1P1 and S1P3 play an important
role in the maintenance of endothelial function. For in-
stance, it has been described that the assembly of junc-
tion proteins to the cell–cell junctions is dependent on
S1P1 and S1P3-induced signaling pathways, involving the
small GTP-ases Rac and Rho [39]. Strikingly, in our
S1P5-deficient brain ECs a significant reduction of S1P1
and S1P3 was detected, indicating that S1P5 is involved
in the expression of these receptors. Given the import-
ance of S1P1 and S1P3 in the maintenance of vascular
function, the reduced barrier function of the brain endo-
thelium due to the lack of S1P5 may also be in part
caused by the lack of S1P1 and S1P3. Together, our find-
ings point to an important function of S1P5 in the regu-
lation of the barrier phenotype of brain ECs.
Besides improving barrier function, the current report
shows that targeting of S1P5 is important for maintenance
of the immunoquiescent state of brain ECs. First, our
results reveal a prominent role for S1P5 in maintaining
low expression levels of leukocyte adhesion molecules, in-
cluding VCAM-1 and ICAM-1, and several important
proinflammatory cytokines and chemokines, such as
TNF-α and MCP-1. In addition, S1P5 activation limits
monocyte adhesion to and migration over the brain endo-
thelial barrier, which is an initial step in the formation of
new MS lesions. Therefore, our findings are of potential
interest for future treatment of neuroinflammatory disor-
ders that are marked by a cellular migration across the
vessel wall. Modulation of the S1P receptors through
FTY720P was shown to be protective in various experi-
mental animal models with neuroinflammation in the
brain [19,40,41]. Moreover, in other vascular disorders,
such as atherosclerosis, FTY720P exerts protective effects
by dampening ongoing inflammatory processes in the vas-
cular smooth muscle cells. In the validated experimental
animal model for MS, experimental allergic encephalomy-
elitis FTY720P was either given as a prophylactic, thera-
peutic or as a rescue agent. In these animals, FTY720P
treatment resulted in a delayed onset of disease and
reduced disease severity through the induction of lympho-
penia. Besides its general immunosuppressive effect,
FTY720P treatment also reduced the expression of vascu-
lar adhesion molecules and cytokines in the spinal cord of
Figure 7 S1P5 knockdown increases monocyte transmigration and adhesion. (a) Adhesion of primary human monocytes to hCMEC/D3,
mock, and S1P5 cells was assayed in time. A significant increase in monocyte adhesion to S1P5 knockdown cells was already observed after 15
minutes (non-targeting control: 112.5%± 3.4; S1P5 knockdown 159.0%± 3.0 at 60 minutes, n = 6). (b) Monocyte migration across confluent
monolayers of hCMEC/D3, mock, and S1P5 knockdown cells was assayed by time-lapse microscopy. A strong increase in monocyte migration of
193% was observed across S1P5 knockdown cells compared to mock cells (non-targeting control: 145.5%± 2.6; S1P5 knockdown: 338.1%± 34.2,
n = 3). (c) VCAM-1 and ICAM-1 gene expression levels in mock and S1P5 knockdown cells were studied by qPCR. VCAM-1 gene expression
increased 204% (non-targeting control: 100.0%± 0.5; S1P5 knockdown 304.4 ± 18.8, n = 3) and ICAM-1 gene expression increased 80%
(non-targeting control: 100.0%± 10.6; S1P5 knockdown 179.6%± 10.8, n = 3) in S1P5 knockdown cells compared to mock cells. (d) FACS
analysis of ICAM-1 and VCAM-1 expression by mock cells and S1P5 knockdown cells demonstrated a 76% (non-targeting control: 100.0%± 6.6; S1P5
knockdown: 175.8%± 13.1, n = 3) increase in ICAM-1 protein expression and a 23% (non-targeting control: 100.0%± 3.1; S1P5 knockdown:
122.8%± 2.7, n = 3) increase in VCAM-1 protein expression by S1P5 knockdown cells. Statistical significance (t-test) is indicated with asterisks:
*P< 0.05, **P< 0.005 and ***P< 0.001.
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mia FTY720P was able to reduce infarct size and could, in
transient focal cerebral ischemia, positively regulate
neurological deficits. Observed beneficial effects were
associated with a reduction in activated neutrophil and
microglia/macrophage cell numbers and, in line with our
results, also with reduced numbers of ICAM-1 positive
blood vessels [41]. However, these studies did not investi-
gate the role of endothelial S1P signaling, which may play
a crucial role in the early onset of disease [40]. Several
in vitro studies support the notion that S1P signaling is
relevant in ECs because it was shown that S1P or/and
FTY720P limit leukocyte adhesion and transmigration
into the vessel wall in the early atherosclerosis pathology.
In addition, S1P1 modulation resulted in reducedendothelial production of TNF-α-induced production of
proinflammatory chemokines [42-44]. Given that both
S1P and FTY720P are general modulators of all S1P
receptors, it remains unclear which specific receptor is
involved in these processes. More specifically, it is unclear
what the role of the brain-specific S1P5 receptor is in these
processes. Our study clearly shows that S1P5 receptors
might play a crucial role in barrier formation and immu-
noquiescence. Although this study utilized a selective
S1P5 receptor agonist, it is important to identify new more
potent and more selective S1P5 tools to fully elucidate the
mechanism by which S1P5 might exert these effects.
We are also the first to show that NF-κB underlies
the anti-inflammatory activity of endothelial S1P5. To
date, no data exist on the downstream signaling
Figure 8 S1P5 mediates immune quiescence of brain
endothelial cells by NF-κB. (a) Protein content of p65 in S1P5
knockdown and control cells was assessed by western blot. The
protein expression of control cells was set as 100%. The S1P5
knockdown cells show an increased expression of about 250%
compared to control. The expression of S1P5 was corrected for actin.
(b) Mock cells and S1P5 knockdown cells were left unexposed or
were exposed to NF-κB inhibitor BAY 11–7085 and ICAM-1 gene
expression levels were determined by qPCR. Upon exposure to BAY
11–7085 ICAM-1 RNA expression in S1P5 knockdown cells decreased
to approximately the same level as in BAY 11–7085 exposed mock
cells. The ratio of reduction in ICAM-1 gene expression by inhibition
of NF-κB in S1P5 knockdown cells increased 2.3-fold compared to
1.6-fold in mock cells. (c) Mock cells and S1P5 knockdown cells were
left unexposed or were exposed to NF-κB inhibitor BAY 11–7085
and VCAM-1 gene expression levels were determined by qPCR.
Upon exposure to BAY 11–7085 VCAM-1 RNA expression in S1P5
knockdown cells decreased to approximately the same level as in
BAY 11–7085 exposed mock cells. The ratio of reduction in VCAM-1
gene expression by inhibition of NF-κB in S1P5 knockdown cells is
increased to 10.3-fold compared to 7.3-fold in mock cells. Data are
expressed as the mean± SEM (n= 3). Statistical significance (t-test) is
indicated with asterisks: *P< 0.05, **P< 0.002 and ***P< 0.001.
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shown that incubation of mouse aortas from type 1
non-obese diabetic mice with S1P reduces VCAM ex-
pression and monocyte adhesion to the endothelium.
The authors also show that S1P1 is the receptor that
mediates this anti-inflammatory response to S1P, which
is related to the inhibition of NFkB translocation to the
nucleus. In accordance with these findings, our results
suggest an anti-inflammatory role for S1P5 in brain ECs.
Furthermore, in Chinese Hamster Ovary-K1 cells it was
demonstrated that S1P5 expression results in inhibition
of extracellular signal-regulated kinase (ERK) activity
[45]. Since ERK activity is a potent regulator of NFκB-
dependent inflammatory responses, this pathway may
be responsible for the observed increase in NF-κB
driven of ICAM-1 and VCAM expression in S1P5
knockdown brain ECs.Conclusion
Together, our novel and provocative findings emphasize
the importance of S1P signaling and in particular S1P5
signaling during health and disease. We demonstrate
that endogenous endothelial S1P5 represents an essential
receptor for optimal BBB function by regulating different
aspects of the BBB, including the expression of cell–cell
junction proteins and efflux pumps. Importantly, we
demonstrate that S1P5 is essential for maintenance of
the immune quiescent state of brain ECs and that this is
in part mediated by NF-κB. Our data also reveal the
therapeutic potential of S1P5 agonism during neuroin-
flammation as S1P5 specifically limits neurovascular in-
flammation and transendothelial leukocyte infiltration.
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